243 related articles for article (PubMed ID: 28559249)
1. MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.
Wu VH; Smith RA; Masoum S; Raugi DN; Ba S; Seydi M; Grobler JA; Gottlieb GS;
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559249
[TBL] [Abstract][Full Text] [Related]
2. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor.
Markowitz M; Sarafianos SG
Curr Opin HIV AIDS; 2018 Jul; 13(4):294-299. PubMed ID: 29697468
[TBL] [Abstract][Full Text] [Related]
3. The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.
Takamatsu Y; Das D; Kohgo S; Hayashi H; Delino NS; Sarafianos SG; Mitsuya H; Maeda K
Cell Chem Biol; 2018 Oct; 25(10):1268-1278.e3. PubMed ID: 30174310
[TBL] [Abstract][Full Text] [Related]
4. Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics.
Muftuoglu Y; Sohl CD; Mislak AC; Mitsuya H; Sarafianos SG; Anderson KS
Antiviral Res; 2014 Jun; 106():1-4. PubMed ID: 24632447
[TBL] [Abstract][Full Text] [Related]
5. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.
Oliveira M; Brenner BG; Xu H; Ibanescu RI; Mesplède T; Wainberg MA
J Antimicrob Chemother; 2017 Nov; 72(11):3008-3011. PubMed ID: 28961903
[TBL] [Abstract][Full Text] [Related]
6. The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.
Smith RA; Raugi DN; Wu VH; Leong SS; Parker KM; Oakes MK; Sow PS; Ba S; Seydi M; Gottlieb GS;
Antimicrob Agents Chemother; 2015 Dec; 59(12):7437-46. PubMed ID: 26392486
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.
Njenda DT; Aralaguppe SG; Singh K; Rao R; Sönnerborg A; Sarafianos SG; Neogi U
J Antimicrob Chemother; 2018 Oct; 73(10):2721-2728. PubMed ID: 30053052
[TBL] [Abstract][Full Text] [Related]
8. Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Maeda K; Desai DV; Aoki M; Nakata H; Kodama EN; Mitsuya H
Antivir Ther; 2014; 19(2):179-89. PubMed ID: 24162098
[TBL] [Abstract][Full Text] [Related]
9. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
Nakata H; Amano M; Koh Y; Kodama E; Yang G; Bailey CM; Kohgo S; Hayakawa H; Matsuoka M; Anderson KS; Cheng YC; Mitsuya H
Antimicrob Agents Chemother; 2007 Aug; 51(8):2701-8. PubMed ID: 17548498
[TBL] [Abstract][Full Text] [Related]
10. Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.
Michailidis E; Ryan EM; Hachiya A; Kirby KA; Marchand B; Leslie MD; Huber AD; Ong YT; Jackson JC; Singh K; Kodama EN; Mitsuya H; Parniak MA; Sarafianos SG
Retrovirology; 2013 Jun; 10():65. PubMed ID: 23800377
[TBL] [Abstract][Full Text] [Related]
11. Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA.
Shanmugasundaram U; Kovarova M; Ho PT; Schramm N; Wahl A; Parniak MA; Garcia JV
PLoS One; 2016; 11(7):e0159517. PubMed ID: 27438728
[TBL] [Abstract][Full Text] [Related]
12. 2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.
Kawamoto A; Kodama E; Sarafianos SG; Sakagami Y; Kohgo S; Kitano K; Ashida N; Iwai Y; Hayakawa H; Nakata H; Mitsuya H; Arnold E; Matsuoka M
Int J Biochem Cell Biol; 2008; 40(11):2410-20. PubMed ID: 18487070
[TBL] [Abstract][Full Text] [Related]
13. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque.
Stoddart CA; Galkina SA; Joshi P; Kosikova G; Moreno ME; Rivera JM; Sloan B; Reeve AB; Sarafianos SG; Murphey-Corb M; Parniak MA
Antimicrob Agents Chemother; 2015 Jul; 59(7):4190-8. PubMed ID: 25941222
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA).
Salie ZL; Kirby KA; Michailidis E; Marchand B; Singh K; Rohan LC; Kodama EN; Mitsuya H; Parniak MA; Sarafianos SG
Proc Natl Acad Sci U S A; 2016 Aug; 113(33):9274-9. PubMed ID: 27489345
[TBL] [Abstract][Full Text] [Related]
16. The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.
Kirby KA; Singh K; Michailidis E; Marchand B; Kodama EN; Ashida N; Mitsuya H; Parniak MA; Sarafianos SG
Cell Mol Biol (Noisy-le-grand); 2011 Feb; 57(1):40-6. PubMed ID: 21366961
[TBL] [Abstract][Full Text] [Related]
17. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.
Michailidis E; Huber AD; Ryan EM; Ong YT; Leslie MD; Matzek KB; Singh K; Marchand B; Hagedorn AN; Kirby KA; Rohan LC; Kodama EN; Mitsuya H; Parniak MA; Sarafianos SG
J Biol Chem; 2014 Aug; 289(35):24533-48. PubMed ID: 24970894
[TBL] [Abstract][Full Text] [Related]
18. Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice.
Hattori S; Ide K; Nakata H; Harada H; Suzu S; Ashida N; Kohgo S; Hayakawa H; Mitsuya H; Okada S
Antimicrob Agents Chemother; 2009 Sep; 53(9):3887-93. PubMed ID: 19546363
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity.
Sohl CD; Singh K; Kasiviswanathan R; Copeland WC; Mitsuya H; Sarafianos SG; Anderson KS
Antimicrob Agents Chemother; 2012 Mar; 56(3):1630-4. PubMed ID: 22155823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
